DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: TYSABRI (natalizumab)
*****************************************************
#Post#: 2063--------------------------------------------------
(AAN) PML risk cut by extending Tysabri dosing interval
By: agate Date: April 27, 2018, 6:23 pm
---------------------------------------------------------
[font=verdana]From Multiple Sclerosis News Today, April 23,
2018--"#AAN2018: PML Risk Cut by Extending Tysabri Dosing
Interval":[/font]
[font=verdana]
HTML https://multiplesclerosisnewstoday.com/2018/04/27/aan2018-pml-risk-cut-by-extending-tysabri-dosing-interval/[/font]
#Post#: 2089--------------------------------------------------
Reducing PML risk with natalizumab
By: agate Date: May 20, 2018, 7:42 pm
---------------------------------------------------------
Another article about this in MedPage Today, May 10,
2018--"Reducing PML risk with natalizumab":
HTML https://www.medpagetoday.com/meetingcoverage/aanposterrounds/72808?xid=nl_mpt_DHE_2018-05-11&eun=g345846d0r&pos=0&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%202018-05-11&utm_term=Daily%20Headlines%20-%20Active%20User%20-%20180%20days
#Post#: 2339--------------------------------------------------
Biogen starts Phase 3b trial to evaluate Tysabri extended dosing
interval
By: agate Date: January 8, 2019, 7:34 pm
---------------------------------------------------------
From Medical News Today, January 7, 2019--"Biogen starts Phase
3B trial to evaluate Tysabri extended interval dosing for RRMS
patients." The dosing regimen being studied would involve
receiving Tysabri every 6 weeks instead of every 4 weeks.
HTML https://multiplesclerosisnewstoday.com/2019/01/07/phase-3b-trial-tysabri-extended-interval-dosing-rrms/
#Post#: 2804--------------------------------------------------
(Abst.) Pharmacodynamics of natalizumab extended interval dosing
in MS
By: agate Date: February 7, 2020, 12:11 am
---------------------------------------------------------
These researchers have found that extended interval dosing of
Tysabri (every 5-8 weeks) doesn't reduce the effectiveness of
the drug.
From PubMed, February 6, 2020--"Pharmacodynamics of natalizumab
extended interval dosing in MS":
HTML https://www.ncbi.nlm.nih.gov/pubmed/32019876
#Post#: 3365--------------------------------------------------
Biogen's results from Phase 3b study comparing Tysabri dosing ev
ery 4 weeks with every 6 weeks
By: agate Date: August 2, 2021, 10:25 pm
---------------------------------------------------------
Biogen's study comparing Tysabri dosing every 4 weeks with
dosing every 6 weeks apparently resulted in an 88% reduction in
the risk of contracting PML with the less-frequent dosing:
From Pipeline Review (August 2, 2021), "Biogen Announces Results
from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with
Natalizumab in Relapsing-Remitting Multiple Sclerosis":
HTML https://bit.ly/37edx03
#Post#: 3672--------------------------------------------------
No significant difference in patient-reported outcomes w/Tysabri
every 6 weeks
By: agate Date: June 5, 2022, 8:37 pm
---------------------------------------------------------
More on this from Neurologylive.com (June 4, 2022), discussing a
study presented at the annual CMSC meeting June 1-4, "No
Significant Difference in Patient-Reported Outcomes with
Natalizumab When Administered Every 6 Weeks":
HTML https://bit.ly/3MmDeNO
*****************************************************